CLC sees skills training, infrastructure and child care as budget highlights

OTTAWA, ONTARIO–(Marketwired – March 22, 2017) – The Canadian Labour Congress says today’s federal budget takes positive steps on a few key issues for working Canadians and their communities.

„We are pleased to see today’s budget invest in several key areas that unions have long championed, including infrastructure, skills training, and child care,” said Canadian Labour Congress President Hassan Yussuff.

„By investing in skills training and infrastructure, including $11 billion in support of a National Housing Strategy, this budget lays the foundation for the creation of good jobs with a social benefit. It also sets the stage for an ongoing, constructive dialogue between government, unions and employer groups to advance skills training in this country,” Yussuff said.

However, Yussuff noted concerns with the establishment of a new Canada Infrastructure Bank, designed to facilitate private investment in public infrastructure, even though reports consistently show these P3 projects are more costly and offer lower-quality jobs and services.

„Government must ensure public infrastructure is publicly financed and operated. We do not need more of the same private-public partnerships that short-change workers and communities,” Yussuff said.

Child care is another issue that has been a top priority for unions for many years, and Yussuff said he was pleased to see the government commit multi-year funding ($7 billion over 10 years) under a national child care framework. This includes 40,000 new subsidized child-care spaces for low- and modest-income families.

„This is an important step in the process towards quality, accessible child care for all Canadian families. Next, the federal, provincial and territorial governments must work to ensure increased funding that is tied to the principles of the Shared Framework on child care,” Yussuff said.

Unions are pleased to see Budget 2017 commit to measures to strengthen Canada’s trade remedy system, including amendments to ensure that unions have the right to participate as interested parties in trade remedy proceedings. Unions will continue to push to ensure unions can also file complaints to initiate proceedings.

However, the CLC expressed disappointment on other issues that impact Canadian workers. First, Employment Insurance, which will continue to leave too many unemployed Canadians behind due to very strict eligibility requirements and inadequate benefits.

Second, on the issue of health care, the CLC welcomes today’s investments in mental health and home care, but had been hoping to see the government commit to stable and long-term health care funding under a national health accord. Unfortunately, this budget maintains the Harper government’s reduction in the Canada Health Transfer, which ensures continued underfunding of the health care system as a whole.

Finally, unions were disappointed that Budget 2017 did not improve the Working Income Tax Benefit, which means it will continue to remain inaccessible for full time, minimum-wage workers.

Science Exchange Named Finalist for Coveted Procurement Leaders World Procurement Awards

/EINPresswire.com/ — PALO ALTO, CA–(Marketwired – Mar 22, 2017) – Science Exchange, the world’s leading marketplace for outsourced research & development, today announced it has been named a finalist for the prestigious World Procurement Awards, the most sought after and recognized accolade in procurement, run by Procurement Leaders. Alongside giants like IBM, Science Exchange is on the short list for the Procurement Service Provider Award.

Science Exchange has been recognized by Procurement Leaders because of its ability to accelerate breakthrough discoveries by giving scientists access to more than 3,000 of the world’s best experimental providers.

As part of its application, Science Exchange shared a case study of a leading BioPharma company that demonstrated the firm had saved 1,180 hours in contracting and legal resources, and 876 hours in procurement and business operations by using Science Exchange’s platform. The firm also measured increased access to innovation by working with more than 50 new suppliers, and saved $1.1M on $10.5M of spend (across 292 orders with 118 scientific service providers) achieving 11% direct cost savings in this category. Surveys of scientists at the firm showed that using Science Exchange saved them 10+ hours per project typically spent identifying a qualified service provider, comparing capabilities, and obtaining quotes; and 2+ months in project initiation by eliminating the need to establish each new supplier contract. With 292 orders processed this can be quantified as 2,920 hours in scientist time savings (292 x 10 hours per order). In addition, 584 months were saved in project initiation (292 x 2 months per order), demonstrating significant potential for cycle time reduction.

„We are thrilled to be recognized by the Procurement Leaders for the work we do here at Science Exchange,” said Dr. Elizabeth Iorns, Founder & CEO of Science Exchange. „Our goal is to make it much more efficient for scientists to advance innovation and bring their vital research to market faster. The top 10 BioPharma companies in the world rely on us to streamline the procurement process for their scientists and researchers, saving them time and money and opening avenues for working with new suppliers. Being shortlisted for this award alongside leaders like IBM really validates the work we are doing in the procurement space.”

The winners of the award will be announced on May 17, 2017 at the World Procurement Awards Ceremony in London.

About Science Exchange
Science Exchange is the world’s leading marketplace for outsourced research. Science Exchange provides an efficient procure-to-pay platform for ordering services from the world’s largest network of scientific service providers. Through Science Exchange, clients gain access to 3000+ qualified service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. This increases scientists access to innovation and significantly improves their productivity because they are freed up from the administrative tasks and delays associated with sourcing, establishing and managing supplier contracts. At an organizational level, the Science Exchange enterprise program enables organizations to consolidate the long tail of research outsourcing spend into a single strategic supplier relationship driving significant efficiency and cost savings. To date, Science Exchange has raised over $30 million from Maverick Capital Ventures, Union Square Ventures, Index Ventures, OATV, the YC Continuity Fund, and others. For more information visit www.scienceexchange.com.

Calgary Airport Authority Once Again One of Alberta’s Top Workplaces

/EINPresswire.com/ — CALGARY, AB–(Marketwired – March 22, 2017) – The Calgary Airport Authority has once again been recognized as a leader in creating one of the best places to work in Alberta.

The Top Employer designation presented by Mediacorp recognizes employers that are committed to creating a vibrant and rewarding work environment. This is the eighth time that the Authority has been acknowledged for creating a great workplace for the Authority employees (also known as the YYC Crew) who are focused on developing, maintaining and operating YYC Calgary International Airport.

„People truly are what makes an organization successful and we know that our 300 employees have an incredible amount of passion for making YYC Calgary International Airport one of the best airport facilities in the country,” said Cynthia Tremblay, Vice President of Human Resources for The Calgary Airport Authority. „Investing in the continued development of our people, and opportunities to grow together by giving back to our community, are just a few examples of what keeps the best and the brightest talent within our organization. We continually hear from our YYC Crew that in addition to the rewarding and very unique work environment, people love working at the Authority because of the great programs we’ve built.”

This year, the Authority will be celebrating its 25-year anniversary with an initiative focused on furthering its engagement programs. The campaign — 25 years, 25 moments — will be employee-driven with the Crew giving back to the Calgary and airport community through various events and initiatives throughout 2017.

The Authority’s key employee offerings include: ongoing professional development, an employee-led engagement program, a robust benefits and pension program, meaningful student work opportunities, and a peer-to-peer recognition program. Additionally, Authority employees have the opportunity to participate in numerous volunteer and social initiatives such as lunchtime yoga, Calgary Corporate Challenge, and opportunities to volunteer at the Mustard Seed.

ABOUT THE CALGARY AIRPORT AUTHORITY

The Calgary Airport Authority is a not-for-profit, non-share capital organization, incorporated under the Alberta Regional Airports Authorities Act, and is responsible for the safe, secure and efficient management of the YYC Calgary International Airport (YYC) and Springbank Airport (YBW) under long-term lease from the Government of Canada. YYC’s mandate is to advance economic and community development by providing improved airline and transportation services for the benefit of the public. The Authority has invested over $4 billion into the continued development of YYC, opening Canada’s longest runway in 2014 and a new International Terminal in 2016. YYC is a key economic driver for Calgary and Alberta, generating more than $8 billion in economic activity annually and creating 48,000 jobs.

Heartland Dental Founder and Executive Chairman Presents at 2017 ADSO Summit

/EINPresswire.com/ — EFFINGHAM, IL–(Marketwired – March 22, 2017) – Rick Workman, DMD, Heartland Dental founder and executive chairman, presented at last week’s Academy of Dental Support Organizations (ADSO) 2017 Summit. The event, held from April 7th – 10th at the Walt Disney World Swan Hotel in Lake Buena Vista, brought leaders from dental support organizations (DSOs) and other dental professionals from around the country together to discuss finding success in group practice, building infrastructure effectively, trends in law and advocacy, and leading change among other topics.

„It’s exciting to see how much the ADSO has grown over the past few years. ADSO member groups now support over 13,000 dentists,” said Dr. Workman. „It was a pleasure to once again be involved with the summit to discuss the future of DSOs, as well as the challenges and opportunities we all face. Having an opportunity like this to collaborate on ideas and solutions is extremely beneficial.”

Additional presenters included author and speaker, Dr. Marc Cooper, professional speaker and healthcare leadership authority, Chip Madera, and many more dental and business leaders. In his presentation, Dr. Workman specifically discussed the early beginnings of the DSO industry and the ADSO, what challenges and advantages DSOs are experiencing today, and what DSOs can do to find success.

„For all DSOs, our collaborative opportunities are huge. As the dentistry profession continues to change, DSOs need to work hard, smart and together. That is how the greatest organizations achieve great success,” added Dr. Workman. „The ADSO has become an ideal means for this collaboration. I can’t wait to see what we can accomplish together for DSOs moving forward, as we help advance the quality of dental care for patients and the quality of life for dental professionals.”

About Heartland Dental

Heartland Dental, LLC is the largest dental support organization in the United States with more than 775 supported dental offices located in 34 states. Based in Effingham, Illinois and founded by Rick Workman, DMD, Heartland Dental offers supported dentists and team members continuing professional education and leadership training, along with a variety of non-clinical administrative services including staffing, human relations, procurement, administration, financial, marketing, and information technology. For more information, visit www.Heartland.com. Follow Heartland Dental on Facebook, Twitter and LinkedIn. Visit Dr. Workman’s Blog, Dentistry Leaders at www.dentistryleaders.com.

Advanced Clean Transportation (ACT) Expo Announces 2017 Keynote and Full Speaker Lineup

/EINPresswire.com/ — SANTA MONICA, CA–(Marketwired – March 22, 2017) – The Advanced Clean Transportation (ACT) Expo, North America’s largest advanced clean transportation event, today announced the featured speaker lineup for its 2017 conference, taking place May 1-4 at the Long Beach Convention Center in Southern California. Throughout the four-day event, attendees will learn from organizations that are driving clean transportation progress across all fleet applications in the midst of an ever-changing market and regulatory environment. All alternative fuels and advanced clean vehicles technologies will be covered — including electric, hybrid, hydrogen, natural gas, propane autogas, renewable diesel, and efficiency technologies. View the full agenda.

„In developing the agenda for the annual ACT Expo, we aim to bring together the leading fleet operators and other industry stakeholders that can share insight into the business case behind their commitment to deploying alternative fuel vehicles and expanding infrastructure,” explained Erik Neandross, CEO of clean transportation consulting firm and producers of the event, GNA. „From mitigating the impact of volatile petroleum prices to proactively addressing continually tightening emissions regulations, attendees will learn how low carbon fuels and advanced vehicle technologies will provide fleets with a competitive advantage in the near- and long-term.”

The opening keynote presentation will be provided by Thom Shea, a highly decorated U.S. Navy SEAL, distinguished author, renowned leadership coach, and president and CEO of Adamantine Alliance. With a number of policy and budget changes at the federal level, and the always present oil price roller coaster, the advanced technology and alternative fuels sectors face continued uncertainty and possible headwinds. Shea will share first-hand accounts from his time as a Navy SEAL and exhilarating insight on how the world’s most successful people can thrive in the face of adversity and uncertainty.

A public policy roundtable will feature leading policymakers and public agencies discuss how the new administration in Washington, DC will shift the landscape for advanced clean transportation technologies and infrastructure. Policy and regulatory influences have always played a critical role in fuel efficiency standards, cleaner engines, and other advanced vehicle technology development, procurement, and deployment — all of which affect fleet operations. Panelists include:

  • Margo Oge, former director of the Office of Transportation Air Quality at the U.S. EPA and author of „Driving the Future: Combating Climate Change with Cleaner, Smarter Cars,” who will provide insight into what to expect over the next four years at the EPA given her more than 30 years with the agency.
  • Randy Frye, State Representative of District 67 at the Indiana State House of Representatives, who worked with U.S. VP Mike Pence to advance alternative fuel vehicles in Indiana.
  • Anne Korin, co-director of the Institute for the Analysis of Global Security (IAGS) and senior adviser to the United States Energy Security Council, who has an in-depth understanding of the effect of petroleum resources in the current geopolitical landscape.
  • Sandra Berg, Vice Chair of the California Air Resources Board, who is urging the state of California to continue leading the nation in the development and deployment of clean transportation solutions.

Other featured speakers include:

  • Mike Casteel, Director of Fleet Procurement, UPS
  • Gary Maresca, Senior Director of Fleet Services, Bimbo Bakeries USA
  • Mark Matheson, CEO & President, Matheson Trucking
  • Kathryn Garcia, Commissioner, New York City Department of Sanitation
  • Pete Melin, Director of Zero Emission Technology, Metro Transit of King County
  • Mike Silva, Civil Engineer & Project Manager, CR&R
  • Kary Schaefer, General Manager of Marketing & Strategy, Daimler Trucks North America
  • Steve Center, VP of Environmental Business Development & Product Regulatory Office, American Honda
  • Bob Myers, Division Chief of Equipment, California Department of Transportation
  • Jonathan Randall, Senior Vice President of North American Sales, Mack Trucks
  • Rob Neitzke, President, Cummins Westport

The 2017 ACT Expo program is planned in partnership with leading industry associations-including the Electric Drive Transportation Association (EDTA), the North American Council for Freight Efficiency (NACFE), Propane Education and Research Council (PERC), Businesses for Social Responsibility (BSR), the California Hydrogen Business Council, Securing America’s Future Energy (SAFE), and the U.S. Department of Energy Clean Cities team, among many others.

Additional speakers, including keynotes, will be announced over the next few weeks. Value registration rates are available until March 31st. For more information, visit www.actexpo.com.

About the Advanced Clean Transportation (ACT) Expo

ACT Expo is North America’s largest clean vehicle event, representing all weight classes and alternative fuels-including electric, hybrid, hydrogen, natural gas, propane autogas, renewable fuels, and advanced technologies. The seventh year conference and expo is set for May 1-4, 2017 in Long Beach, California and is expected to assemble thousands of attendees from across the advanced vehicle and alternative fuels industries. The annual event is produced by Gladstein, Neandross & Associates (GNA), the leading North American consulting firm specializing in market development for low-emission and alternative fuel vehicle technologies, infrastructure and fuels for both on and off-road applications. GNA and Penton Trucking, the transportation industry’s leading business intelligence provider and home of many premier brands for trucking insights, formed a strategic partnership in 2017 to further grow the annual event. Learn more at www.actexpo.com and www.gladstein.org

Immunotec Enters Into Agreement to Be Acquired

VAUDREUIL-DORION, QUEBEC–(Marketwired – March 22, 2017) – Immunotec Inc. (TSX VENTURE:IMM) („Immunotec” or the „Company”) announced today that it has entered into a definitive agreement (the „Arrangement Agreement”) with 1111267 B.C. Ltd., a subsidiary of Immuno Holding S.A. de C.V. („Immuno Holding”), pursuant to which Immuno Holding is expected to acquire all of the issued and outstanding common shares of the Company („Shares”) for a cash consideration of $0.485 per Share (the „Transaction”). The consideration represents a premium of 22.8% to the closing price of the Shares on the TSX Venture Exchange (the „Exchange”) on March 21, 2017 and of 22.4% to the volume weighted average trading price of the Shares on the Exchange for the 20-day period ending on March 21, 2017.

Shareholders holding in excess of 66 2/3% of the outstanding Shares have expressed their support of the Transaction, including the founding shareholders and other shareholders, directors and officers of the Company who have entered into voting support agreements in respect of 60.28% of the outstanding Shares pursuant to which they have undertaken to vote in favour of the Transaction at the special meeting of shareholders to be called in order to approve the Transaction, and, in the case of the founding shareholders, regardless of whether a superior proposal emerges.

The agreement reached with Immuno Holding concludes a strategic review process that was initiated by Immunotec in response to the desire expressed by Charles Roberts and Dieter Beer, two of its founding shareholders, to monetize their interests in the Company as part their personal estate planning while ensuring that the new owners possess the resources and experience required to drive the Company’s continued growth in the future. Mr. Roberts will remain as Chairman Emeritus of Immunotec and Mr. John Molson, who is also a founding shareholder, will continue as a key member of the executive team, helping ensure the continuity of the R&D culture originally established by Dr. Gustavo Bounous and Dr. Patricia Kongshavn. These founding shareholders, who created Immunotec in 1996, own or control an aggregate of 58.5% of the outstanding Shares.

Immuno Holding is a company led by Mauricio Domenzain in partnership with Nexxus Capital, one of the leading alternative asset managers in Mexico with a track record of almost 20 years of investing in and supporting successful growth companies.

Mr. Domenzain is a former top executive of a prominent global direct selling company, with relevant expertise in the Mexican and US markets and a passion for the network marketing industry.

„We are very excited about this transaction, as we believe that Immunotec, with its strong management team, its network of over 100,000 independent consultants, and its culture rooted in Quebec-based research and development, is uniquely positioned to continue to generate growth and prosperity for the benefit of its customers, independent consultants and employees in Quebec, the U.S. and Mexico,” said Mauricio Domenzain. „We have great respect for Immunotec’s leadership team guided by Charlie Orr, CEO, as well as the independent consultants and look forward to working collaboratively to fuel such growth and to support the current momentum Immunotec has been experiencing over these past years.”

Charlie Orr added: „We are most excited about moving our aspirations forward together with Immuno Holding to unleash the Company’s growth potential.”

Rod Budd, Chairman of the Board of Directors of Immunotec, added: „We believe the time is right to take this next step in the evolution of Immunotec. After undertaking a robust strategic review effort, led by Threadstone Advisors LLC, we are excited by the value to be delivered to Immunotec’s shareholders. The Board was also very impressed by Immuno Holding’s understanding of our relevant markets as well as their excellent plan to maintain, and accelerate, the Company’s growth. This transaction presents the ideal opportunity for all stakeholders.”

Charles Roberts, one of the Company’s founders, added: „I believe Immuno Holding will bring great experience, dynamism and support to Immunotec’s employees and network of independent consultants in order to foster the Company’s continued path of growth and success”. Dieter Beer, another founder, added: „I have confidence that with Immuno Holding’s support, the Company will continue the vision that I shared with Dr. Bounous to position Immunocal® as a global nutritional choice, and to improve many more lives with this incredible product.”

Transaction Terms

The Transaction is expected to be completed by way of a statutory plan of arrangement under the Canada Business Corporations Act and is subject to court approval, the approval of the holders of Shares representing, in the aggregate, not less than 66 2/3% of the votes cast in respect of the Transaction, the approval of the holders of Shares representing, in the aggregate, a majority of the votes cast in respect of the Transaction by holders other than those who have an interest in the Transaction and the satisfaction of customary conditions.

The Transaction has been unanimously approved by the board of directors of Immunotec (with Messrs. Roberts and Beer abstaining due to their interests as significant shareholders of Immunotec) following the unanimous recommendation of a special committee of independent directors. Ernst & Young LLP, as fairness advisor to the board of directors of Immunotec, has provided an opinion (the „Fairness Opinion”) that, as of March 22, 2017, subject to the assumptions, qualifications and limitations provided therein, the consideration to be received by the shareholders pursuant to the Transaction is fair, from a financial point of view, to the shareholders.

A special meeting of the shareholders of Immunotec (the „Special Meeting”) is expected to be held in May, 2017, at which shareholders of the Company will be asked to approve the Transaction. Further information regarding the Transaction, including the Fairness Opinion, will be included in the information circular that will be mailed by Immunotec to its shareholders in advance of the Special Meeting and will be available under the profile of Immunotec at www.sedar.com. It is expected that the Transaction will close in June, 2017.

The Arrangement Agreement contains customary clauses for transactions of this nature, including a prohibition against the Company soliciting or initiating any inquiries or discussion regarding any other business combination or sale of assets, subject to the fiduciary duty of the board of directors of Immunotec in the event that an unsolicited superior proposal is received by the Company and the right in favour of Immuno Holding to match any superior proposal. Subject to certain limited exceptions, the Arrangement Agreement may not be terminated by Immunotec in the event of a superior proposal, such that the vote in respect of the Transaction will nonetheless be required to take place at the Special Meeting in such a situation. A termination fee of $2,000,000 is payable to Immuno Holding in certain circumstances, including if Immuno Holding fails to exercise its right to match in the context of a superior proposal and elects to terminate the Arrangement Agreement.

About Immunotec

Immunotec is a Canadian-based company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S., Mexico, the Dominican Republic, the United Kingdom and Ireland. The Company offers an extensive line of nutritional, skin care and wellness products targeting health, weight management, energy and physical performance. Please visit us at www.immunotec.com for additional information.

The Company files its continuous disclosure documents, inclusive of its year end results, on the SEDAR database at www.sedar.com and on the Company’s website at www.immunotec.com. The Shares of the Company are listed on the Exchange under the ticker symbol IMM.

Forward Looking Statements

This press release contains statements that constitute „forward-looking information” or „forward-looking statements” (collectively „forward-looking information”) within the meaning of applicable securities legislation. Forward-looking information is often, but not always, identified by the use of words such as „anticipate”, „believe”, „expect”, „plan”, „intend”, „forecast”, „target”, „project”, „may”, „will”, „should”, „could” or similar words suggesting future outcomes or language suggesting an outlook.

Forward-looking information contained in this press release is based on the current beliefs of the Company as well as assumptions made by, and information currently available to, the Company. Although the Company considers these assumptions to be reasonable based on information currently available, they may prove to be incorrect.

By its very nature, the forward-looking information included in this press release involves inherent risks and uncertainties, both general and specific, and risks that predictions, forecasts, projections and other forward-looking information will not be achieved. Readers are cautioned not to place undue reliance on this forward-looking information as a number of important factors could cause the actual results to differ materially from those expressed in such forward-looking information. These factors include, but are not limited to, those risks associated with obtaining all of the judicial, regulatory and securityholder approvals necessary to allow for the completion of the Transaction in accordance with its terms. Readers are cautioned that the foregoing list of factors that may affect future results is not exhaustive. For information identifying further known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking information, please refer to the heading „Risks and Uncertainties” in Immunotec’s most recent Management’s Discussion and Analysis which can be found at www.sedar.com. When relying on forward-looking information to make decisions with respect Immunotec, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Furthermore, the forward-looking information contained in this press release is made as of the date of this press release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Immunotec Enters Into Agreement to Be Acquired

VAUDREUIL-DORION, QUEBEC–(Marketwired – March 22, 2017) – Immunotec Inc. (TSX VENTURE:IMM) („Immunotec” or the „Company”) announced today that it has entered into a definitive agreement (the „Arrangement Agreement”) with 1111267 B.C. Ltd., a subsidiary of Immuno Holding S.A. de C.V. („Immuno Holding”), pursuant to which Immuno Holding is expected to acquire all of the issued and outstanding common shares of the Company („Shares”) for a cash consideration of $0.485 per Share (the „Transaction”). The consideration represents a premium of 22.8% to the closing price of the Shares on the TSX Venture Exchange (the „Exchange”) on March 21, 2017 and of 22.4% to the volume weighted average trading price of the Shares on the Exchange for the 20-day period ending on March 21, 2017.

Shareholders holding in excess of 66 2/3% of the outstanding Shares have expressed their support of the Transaction, including the founding shareholders and other shareholders, directors and officers of the Company who have entered into voting support agreements in respect of 60.28% of the outstanding Shares pursuant to which they have undertaken to vote in favour of the Transaction at the special meeting of shareholders to be called in order to approve the Transaction, and, in the case of the founding shareholders, regardless of whether a superior proposal emerges.

The agreement reached with Immuno Holding concludes a strategic review process that was initiated by Immunotec in response to the desire expressed by Charles Roberts and Dieter Beer, two of its founding shareholders, to monetize their interests in the Company as part their personal estate planning while ensuring that the new owners possess the resources and experience required to drive the Company’s continued growth in the future. Mr. Roberts will remain as Chairman Emeritus of Immunotec and Mr. John Molson, who is also a founding shareholder, will continue as a key member of the executive team, helping ensure the continuity of the R&D culture originally established by Dr. Gustavo Bounous and Dr. Patricia Kongshavn. These founding shareholders, who created Immunotec in 1996, own or control an aggregate of 58.5% of the outstanding Shares.

Immuno Holding is a company led by Mauricio Domenzain in partnership with Nexxus Capital, one of the leading alternative asset managers in Mexico with a track record of almost 20 years of investing in and supporting successful growth companies.

Mr. Domenzain is a former top executive of a prominent global direct selling company, with relevant expertise in the Mexican and US markets and a passion for the network marketing industry.

„We are very excited about this transaction, as we believe that Immunotec, with its strong management team, its network of over 100,000 independent consultants, and its culture rooted in Quebec-based research and development, is uniquely positioned to continue to generate growth and prosperity for the benefit of its customers, independent consultants and employees in Quebec, the U.S. and Mexico,” said Mauricio Domenzain. „We have great respect for Immunotec’s leadership team guided by Charlie Orr, CEO, as well as the independent consultants and look forward to working collaboratively to fuel such growth and to support the current momentum Immunotec has been experiencing over these past years.”

Charlie Orr added: „We are most excited about moving our aspirations forward together with Immuno Holding to unleash the Company’s growth potential.”

Rod Budd, Chairman of the Board of Directors of Immunotec, added: „We believe the time is right to take this next step in the evolution of Immunotec. After undertaking a robust strategic review effort, led by Threadstone Advisors LLC, we are excited by the value to be delivered to Immunotec’s shareholders. The Board was also very impressed by Immuno Holding’s understanding of our relevant markets as well as their excellent plan to maintain, and accelerate, the Company’s growth. This transaction presents the ideal opportunity for all stakeholders.”

Charles Roberts, one of the Company’s founders, added: „I believe Immuno Holding will bring great experience, dynamism and support to Immunotec’s employees and network of independent consultants in order to foster the Company’s continued path of growth and success”. Dieter Beer, another founder, added: „I have confidence that with Immuno Holding’s support, the Company will continue the vision that I shared with Dr. Bounous to position Immunocal® as a global nutritional choice, and to improve many more lives with this incredible product.”

Transaction Terms

The Transaction is expected to be completed by way of a statutory plan of arrangement under the Canada Business Corporations Act and is subject to court approval, the approval of the holders of Shares representing, in the aggregate, not less than 66 2/3% of the votes cast in respect of the Transaction, the approval of the holders of Shares representing, in the aggregate, a majority of the votes cast in respect of the Transaction by holders other than those who have an interest in the Transaction and the satisfaction of customary conditions.

The Transaction has been unanimously approved by the board of directors of Immunotec (with Messrs. Roberts and Beer abstaining due to their interests as significant shareholders of Immunotec) following the unanimous recommendation of a special committee of independent directors. Ernst & Young LLP, as fairness advisor to the board of directors of Immunotec, has provided an opinion (the „Fairness Opinion”) that, as of March 22, 2017, subject to the assumptions, qualifications and limitations provided therein, the consideration to be received by the shareholders pursuant to the Transaction is fair, from a financial point of view, to the shareholders.

A special meeting of the shareholders of Immunotec (the „Special Meeting”) is expected to be held in May, 2017, at which shareholders of the Company will be asked to approve the Transaction. Further information regarding the Transaction, including the Fairness Opinion, will be included in the information circular that will be mailed by Immunotec to its shareholders in advance of the Special Meeting and will be available under the profile of Immunotec at www.sedar.com. It is expected that the Transaction will close in June, 2017.

The Arrangement Agreement contains customary clauses for transactions of this nature, including a prohibition against the Company soliciting or initiating any inquiries or discussion regarding any other business combination or sale of assets, subject to the fiduciary duty of the board of directors of Immunotec in the event that an unsolicited superior proposal is received by the Company and the right in favour of Immuno Holding to match any superior proposal. Subject to certain limited exceptions, the Arrangement Agreement may not be terminated by Immunotec in the event of a superior proposal, such that the vote in respect of the Transaction will nonetheless be required to take place at the Special Meeting in such a situation. A termination fee of $2,000,000 is payable to Immuno Holding in certain circumstances, including if Immuno Holding fails to exercise its right to match in the context of a superior proposal and elects to terminate the Arrangement Agreement.

About Immunotec

Immunotec is a Canadian-based company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S., Mexico, the Dominican Republic, the United Kingdom and Ireland. The Company offers an extensive line of nutritional, skin care and wellness products targeting health, weight management, energy and physical performance. Please visit us at www.immunotec.com for additional information.

The Company files its continuous disclosure documents, inclusive of its year end results, on the SEDAR database at www.sedar.com and on the Company’s website at www.immunotec.com. The Shares of the Company are listed on the Exchange under the ticker symbol IMM.

Forward Looking Statements

This press release contains statements that constitute „forward-looking information” or „forward-looking statements” (collectively „forward-looking information”) within the meaning of applicable securities legislation. Forward-looking information is often, but not always, identified by the use of words such as „anticipate”, „believe”, „expect”, „plan”, „intend”, „forecast”, „target”, „project”, „may”, „will”, „should”, „could” or similar words suggesting future outcomes or language suggesting an outlook.

Forward-looking information contained in this press release is based on the current beliefs of the Company as well as assumptions made by, and information currently available to, the Company. Although the Company considers these assumptions to be reasonable based on information currently available, they may prove to be incorrect.

By its very nature, the forward-looking information included in this press release involves inherent risks and uncertainties, both general and specific, and risks that predictions, forecasts, projections and other forward-looking information will not be achieved. Readers are cautioned not to place undue reliance on this forward-looking information as a number of important factors could cause the actual results to differ materially from those expressed in such forward-looking information. These factors include, but are not limited to, those risks associated with obtaining all of the judicial, regulatory and securityholder approvals necessary to allow for the completion of the Transaction in accordance with its terms. Readers are cautioned that the foregoing list of factors that may affect future results is not exhaustive. For information identifying further known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking information, please refer to the heading „Risks and Uncertainties” in Immunotec’s most recent Management’s Discussion and Analysis which can be found at www.sedar.com. When relying on forward-looking information to make decisions with respect Immunotec, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Furthermore, the forward-looking information contained in this press release is made as of the date of this press release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Immunotec Enters Into Agreement to Be Acquired

VAUDREUIL-DORION, QUEBEC–(Marketwired – March 22, 2017) – Immunotec Inc. (TSX VENTURE:IMM) („Immunotec” or the „Company”) announced today that it has entered into a definitive agreement (the „Arrangement Agreement”) with 1111267 B.C. Ltd., a subsidiary of Immuno Holding S.A. de C.V. („Immuno Holding”), pursuant to which Immuno Holding is expected to acquire all of the issued and outstanding common shares of the Company („Shares”) for a cash consideration of $0.485 per Share (the „Transaction”). The consideration represents a premium of 22.8% to the closing price of the Shares on the TSX Venture Exchange (the „Exchange”) on March 21, 2017 and of 22.4% to the volume weighted average trading price of the Shares on the Exchange for the 20-day period ending on March 21, 2017.

Shareholders holding in excess of 66 2/3% of the outstanding Shares have expressed their support of the Transaction, including the founding shareholders and other shareholders, directors and officers of the Company who have entered into voting support agreements in respect of 60.28% of the outstanding Shares pursuant to which they have undertaken to vote in favour of the Transaction at the special meeting of shareholders to be called in order to approve the Transaction, and, in the case of the founding shareholders, regardless of whether a superior proposal emerges.

The agreement reached with Immuno Holding concludes a strategic review process that was initiated by Immunotec in response to the desire expressed by Charles Roberts and Dieter Beer, two of its founding shareholders, to monetize their interests in the Company as part their personal estate planning while ensuring that the new owners possess the resources and experience required to drive the Company’s continued growth in the future. Mr. Roberts will remain as Chairman Emeritus of Immunotec and Mr. John Molson, who is also a founding shareholder, will continue as a key member of the executive team, helping ensure the continuity of the R&D culture originally established by Dr. Gustavo Bounous and Dr. Patricia Kongshavn. These founding shareholders, who created Immunotec in 1996, own or control an aggregate of 58.5% of the outstanding Shares.

Immuno Holding is a company led by Mauricio Domenzain in partnership with Nexxus Capital, one of the leading alternative asset managers in Mexico with a track record of almost 20 years of investing in and supporting successful growth companies.

Mr. Domenzain is a former top executive of a prominent global direct selling company, with relevant expertise in the Mexican and US markets and a passion for the network marketing industry.

„We are very excited about this transaction, as we believe that Immunotec, with its strong management team, its network of over 100,000 independent consultants, and its culture rooted in Quebec-based research and development, is uniquely positioned to continue to generate growth and prosperity for the benefit of its customers, independent consultants and employees in Quebec, the U.S. and Mexico,” said Mauricio Domenzain. „We have great respect for Immunotec’s leadership team guided by Charlie Orr, CEO, as well as the independent consultants and look forward to working collaboratively to fuel such growth and to support the current momentum Immunotec has been experiencing over these past years.”

Charlie Orr added: „We are most excited about moving our aspirations forward together with Immuno Holding to unleash the Company’s growth potential.”

Rod Budd, Chairman of the Board of Directors of Immunotec, added: „We believe the time is right to take this next step in the evolution of Immunotec. After undertaking a robust strategic review effort, led by Threadstone Advisors LLC, we are excited by the value to be delivered to Immunotec’s shareholders. The Board was also very impressed by Immuno Holding’s understanding of our relevant markets as well as their excellent plan to maintain, and accelerate, the Company’s growth. This transaction presents the ideal opportunity for all stakeholders.”

Charles Roberts, one of the Company’s founders, added: „I believe Immuno Holding will bring great experience, dynamism and support to Immunotec’s employees and network of independent consultants in order to foster the Company’s continued path of growth and success”. Dieter Beer, another founder, added: „I have confidence that with Immuno Holding’s support, the Company will continue the vision that I shared with Dr. Bounous to position Immunocal® as a global nutritional choice, and to improve many more lives with this incredible product.”

Transaction Terms

The Transaction is expected to be completed by way of a statutory plan of arrangement under the Canada Business Corporations Act and is subject to court approval, the approval of the holders of Shares representing, in the aggregate, not less than 66 2/3% of the votes cast in respect of the Transaction, the approval of the holders of Shares representing, in the aggregate, a majority of the votes cast in respect of the Transaction by holders other than those who have an interest in the Transaction and the satisfaction of customary conditions.

The Transaction has been unanimously approved by the board of directors of Immunotec (with Messrs. Roberts and Beer abstaining due to their interests as significant shareholders of Immunotec) following the unanimous recommendation of a special committee of independent directors. Ernst & Young LLP, as fairness advisor to the board of directors of Immunotec, has provided an opinion (the „Fairness Opinion”) that, as of March 22, 2017, subject to the assumptions, qualifications and limitations provided therein, the consideration to be received by the shareholders pursuant to the Transaction is fair, from a financial point of view, to the shareholders.

A special meeting of the shareholders of Immunotec (the „Special Meeting”) is expected to be held in May, 2017, at which shareholders of the Company will be asked to approve the Transaction. Further information regarding the Transaction, including the Fairness Opinion, will be included in the information circular that will be mailed by Immunotec to its shareholders in advance of the Special Meeting and will be available under the profile of Immunotec at www.sedar.com. It is expected that the Transaction will close in June, 2017.

The Arrangement Agreement contains customary clauses for transactions of this nature, including a prohibition against the Company soliciting or initiating any inquiries or discussion regarding any other business combination or sale of assets, subject to the fiduciary duty of the board of directors of Immunotec in the event that an unsolicited superior proposal is received by the Company and the right in favour of Immuno Holding to match any superior proposal. Subject to certain limited exceptions, the Arrangement Agreement may not be terminated by Immunotec in the event of a superior proposal, such that the vote in respect of the Transaction will nonetheless be required to take place at the Special Meeting in such a situation. A termination fee of $2,000,000 is payable to Immuno Holding in certain circumstances, including if Immuno Holding fails to exercise its right to match in the context of a superior proposal and elects to terminate the Arrangement Agreement.

About Immunotec

Immunotec is a Canadian-based company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S., Mexico, the Dominican Republic, the United Kingdom and Ireland. The Company offers an extensive line of nutritional, skin care and wellness products targeting health, weight management, energy and physical performance. Please visit us at www.immunotec.com for additional information.

The Company files its continuous disclosure documents, inclusive of its year end results, on the SEDAR database at www.sedar.com and on the Company’s website at www.immunotec.com. The Shares of the Company are listed on the Exchange under the ticker symbol IMM.

Forward Looking Statements

This press release contains statements that constitute „forward-looking information” or „forward-looking statements” (collectively „forward-looking information”) within the meaning of applicable securities legislation. Forward-looking information is often, but not always, identified by the use of words such as „anticipate”, „believe”, „expect”, „plan”, „intend”, „forecast”, „target”, „project”, „may”, „will”, „should”, „could” or similar words suggesting future outcomes or language suggesting an outlook.

Forward-looking information contained in this press release is based on the current beliefs of the Company as well as assumptions made by, and information currently available to, the Company. Although the Company considers these assumptions to be reasonable based on information currently available, they may prove to be incorrect.

By its very nature, the forward-looking information included in this press release involves inherent risks and uncertainties, both general and specific, and risks that predictions, forecasts, projections and other forward-looking information will not be achieved. Readers are cautioned not to place undue reliance on this forward-looking information as a number of important factors could cause the actual results to differ materially from those expressed in such forward-looking information. These factors include, but are not limited to, those risks associated with obtaining all of the judicial, regulatory and securityholder approvals necessary to allow for the completion of the Transaction in accordance with its terms. Readers are cautioned that the foregoing list of factors that may affect future results is not exhaustive. For information identifying further known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking information, please refer to the heading „Risks and Uncertainties” in Immunotec’s most recent Management’s Discussion and Analysis which can be found at www.sedar.com. When relying on forward-looking information to make decisions with respect Immunotec, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Furthermore, the forward-looking information contained in this press release is made as of the date of this press release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Domo Introduces Domo Everywhere, a New Offering That Extends Its Award-Winning, Real-Time Data Experience to Millions of Partners and Customers Worldwide

Jay Heglar, Domo’s Chief Strategy Officer and Former Amazon Executive, to Lead Program

SILICON SLOPES, UT–(Marketwired – March 22, 2017) – Today Domo announced Domo Everywhere, a new offering that gives Domo customers the ability to make business data from Domo — such as user behavior, business inventory levels, customer order history or member benefits — more easily accessible, interactive and consumable to their customers and partners worldwide. Jay Heglar, Domo’s Chief Strategy Officer, and previously the head of the enterprise business at Amazon Web Services, will lead the program.

„Domo makes data available for everyone and now our customers can make it available everywhere,” said Josh James, founder and CEO of Domo. „The significant emphasis we’ve had on building a very powerful integrated stack, plus our maniacal focus on the user experience, allows Domo to be shared everywhere in a very secure, seamless and scaleable way.”

James added, „Jay’s experience in go-to-market strategies for cloud-savvy enterprises will ensure that Domo is extended far and wide, meeting the demands of global enterprises everywhere.”

Domo Everywhere includes three distinct offerings, giving customers choices in how they leverage their own brand alongside the Domo experience.

Domo White Label: Leverage the Domo experience under your own brand

  • With Domo White Label, business-to-consumer and business-to-business organizations such as retailers, technology companies, manufacturers, media companies and advertising agencies can easily deliver the complete Domo experience with their customers, vendors or partners under their own brand.

Domo Embed: Share real-time data from Domo via your website, customer-facing portal or custom app

  • Domo Embed is the industry’s first embedded analytics solution that makes it possible for organizations to share and personalize the real-time data from inside Domo with relevant people outside the company via a branded website, customer-facing portal or custom app. With Domo Embed, customers can leverage their existing visualizations and datasets, further accelerating the time to value and ROI from the platform.

Domo Publish: Share real-time data from Domo with a unique URL

  • Domo Publish is a sharing option for customers who need to give ad hoc data access to people or groups. This solution allows customers to create a protected area within Domo and assign a unique log-in for data access. Domo Publish is ideal for situations when customers need an efficient and secure method for sharing data. Some use cases for Domo Publish include providing access to key performance metrics for the Board, or providing contractors with access to the specific data they need to perform their tasks.

Domo Everywhere leverages built in single-sign-on integration and personalized data segregation to assure organizations they can deliver a seamless, secure and personalized experience to their customers and partners regardless of how the data is shared. Domo Everywhere builds on existing options for sharing real-time data from the Domo platform such as Buzz, scheduled reports, slides shows, and Microsoft Word and PowerPoint integrations.

In addition to Domo Everywhere, today Domo also announced several new features to The Business Cloud to further revolutionize the way business is managed. These new, highly intuitive capabilities continue to advance customers’ ability to drive rapid ROI with the Domo platform and improve business performance.

Domo Everywhere will be available in late Spring 2017. For more information, go to https://www.domo.com/product/dp17-announcements.

About Domo
Domo helps all employees — from the CEO to the front line worker — optimize business performance by connecting them to the right data and people they need to improve business results. Domo’s Business Cloud is the world’s first customizable platform that enables decision makers to identify and act on strategic opportunities in real time. The company is backed with more than $500 million from the world’s best investors and is led by a management team with tenure at the world’s most well-known technology companies. For more information, visit www.domo.com. You can also follow Domo on Twitter, Facebook, LinkedIn, Google+, Instagram and Pinterest.

Domo, The Business Cloud, Domo White Label, Domo Embed, Domo Publish and Domo Everywhere are trademarks of Domo, Inc.

Local Forces Launch Daring Assault Behind Enemy Lines in Syria

WASHINGTON, March 22, 2017 — Local forces in Syria launched a multi-pronged offensive that included a daring air assault behind enemy lines to liberate Tabqa Dam, located 25 miles upstream from the city of Raqqa, the Combined Joint Task Force Operation Inherent Resolve public affairs officer said today.

Army Col. Joseph E. Scrocca conducted a teleconference live from Baghdad with the Pentagon press corps to detail the operation planned and carried out by the Syrian Defense Forces and their Syrian Arab Coalition partners with support from the international coalition to defeat the Islamic State of Iraq and Syria.

The SDF liberation of Tabqa is critical to isolating Raqqa and the next step toward annihilating ISIS in Syria, Scrocca said, adding that the dam, city and airfield are critical to ISIS for importing and harboring foreign fighters and exporting terror.

The Tabqa locations are ISIS’s last link to their territory west of the Euphrates River, he said.

Isolating Raqqa

Scrocca said Tabqa Dam has been used as an ISIS headquarters, a prison for high-profile hostages and a training site for ISIS leaders. Tabqa also has housed fighter-terrorist training camps and has served as a control center for terrorist attacks against the West since ISIS took control of the location in 2013.

“Seizing Tabqa dam will isolate Raqqa from three sides and give the SDF a strategic advantage and the launching point they need to liberate the city,” he said.

A key element of the coalition’s strategy against ISIS is to work by, with and through committed and capable local partner forces fighting to liberate their people and their land, Scrocca said.

“The SDF and the local Syrian Arab Coalition fighters have proven to be the most effective ground force against ISIS in Syria, he added, “and they have proved it once again with this daring operation.”

The international coalition supported the offensive with air movement and logistical support, precision airstrikes, close-air support by Apache helicopters, Marine Corps artillery and special operations advice and assistance to SDF leadership, Scrocca said.

Fighting ISIS in Syria, Iraq

Over the last four months the coalition has conducted more than 300 airstrikes around Tabqa and to the west of Raqqa, and has killed hundreds of enemy fighters and destroyed more than 200 fortifications and more than 50 ISIS vehicles, the OIR spokesman said.

“But make no mistake about it,” Scrocca said. “It is SDF on the ground putting their lives at risk and valiantly engaging the enemy. … It is the Syrian Democratic Forces, like the Iraqi security forces, who are making the sacrifices so that other coalition nations do not continue to suffer the threat of ISIS terrorism inside their own borders.”

Turning to Mosul in Iraq, Scrocca said that while Iraqi Prime Minister Haider al-Abadi was meeting yesterday at the White House with President Donald J. Trump, Iraqi forces continued to pressure ISIS on multiple axes of advance in or around the western part of the city.

“It is grueling, bloody, tough fighting against a brutal and entrenched enemy who cares nothing about the local citizens and deliberately targets them as the [Iraqis] try to evacuate them from the front lines,” the OIR spokesman said, “… but the [Iraqis] are not backing down.”

Scrocca added, “This is what building partner capacity looks like on the ground. This is what the coalition has strived to instill in these soldiers and police through our training. The ‘by, with and through’ strategy is working, and we know that because we’ve seen what these forces are doing every day against a truly evil enemy.”

(Follow Cheryl Pellerin on Twitter: @PellerinDoDNews)